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In order to gain further insight on the role of Kaposi’s sarcoma-associated herpesvirus (KSHV) in classic and
endemic Kaposi’s sarcoma (KS) pathogenesis, we aimed to determine (i) whether KSHV is detectable in
peripheral blood mononuclear cells (PBMCs), (ii) which PBMCs subpopulation harbor the virus, (iii) which
clinical, histologic, and immunologic parameters are associated with KSHV viremia in a population of classic
and endemic KS. KSHV viremia and various immunologic parameters were screened on 81 patients. KSHV
viremia was positive in 58% of the patients. KSHV was detected in B cells, T cells, and monocytes. CD34þ cells
depleted in circulating endothelial cells (CECs) were never infected and 50% of the patients tested had CECs
infected by KSHV. We observed a significant increase of IL-2 and IFN-g production by CD4 T cells and an
increase of IFN-g production by CD8 T cells compared to control patients. KS progression (P¼ 0.001) and KS
staging (P¼ 0.03) were significantly and independently associated with positive KSHV viremia. Our results show
that there is no specific immunosuppression in classic or endemic KS. We showed that KSHV can be detected
within CECs and that KSHV viremia could be an indicator of circulating mature or precursor spindle cells.
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INTRODUCTION
Kaposi’s sarcoma (KS) is regarded as a multicentric neoplasm
of lymphatic endothelium infected with Kaposi’s sarcoma-
associated herpesvirus (KSHV) (Chang et al., 1994; Antman
and Chang, 2000).
Three contexts for KS can be distinguished by clinico-
epidemiologic features, all characterized by frequent cuta-
neous lesions: classic KS (CKS) affecting mostly men from
Mediterranean countries with an indolent course; endemic
KS (EKS) in people from sub-Saharan Africa with either
indolent or locally aggressive cutaneous lesions; KS in
immunosuppressed patients, either iatrogenically or with
HIV infection, with progressive cutaneous disease and
frequently serious visceral lesions (Antman and Chang,
2000).
KSHV infects most spindle cells of the KS lesions (Boshoff
et al., 1995). Spindle cells are endothelial cells expressing
various specific lymphatic lineage proteins. Whether KSHV
infects endothelial precursors and drives them to differenti-
ate, or, equally, infects mature lymphatic and blood endo-
thelial cells and induces gene expression similar those in to
lymphatic cells is debated (Hong et al., 2004; Wang et al.,
2004). The virus has been detected in all the major
populations of peripheral blood mononuclear cells (PBMCs):
B and T lymphocytes and monocytes (Ambroziak et al., 1995;
Harrington et al., 1996; Henry et al., 1999). Henry et al.
(1999) also showed that KSHV may infect PBMC CD34 cells.
We previously showed that KSHV virus levels in PBMCs
correlated with both the degree of immunosuppression and
KS progression, in epidemic and iatrogenic KS, suggesting
KSHV reactivation parallels the decrease in immune surveil-
lance (Pellet et al., 2001, 2002). To our knowledge, immune
suppression has not been unequivocally demonstrated in CKS
or EKS, and apart from age and sex, the risk factors for KS
among KSHV-positive, HIV-negative persons without overt
immune suppression are unknown. Genetic cofactors such as
variant genotypes of FcgammaRIIIA (Lehrnbecher et al.,
2000) or IL6 promoter polymorphism (Foster et al., 2000) as
demonstrated for HIV-related KS or a unknown recessive
gene (Plancoulaine et al., 2003) could also be involved in
CKS or EKS.
See related commentary on page 545
& 2006 The Society for Investigative Dermatology www.jidonline.org 621
ORIGINAL ARTICLE
Received 7 June 2005; revised 30 September 2005; accepted 21 October
2005; published online 12 January 2006
1Laboratory of Pharmacology, INSERM U716, Saint-Louis Hospital, Paris,
France; 2Department of Dermatology, Saint-Louis Hospital, Paris, France;
3Laboratory of Immunology and Histocompatibility, Saint-Louis Hospital,
Paris, France; 4Laboratory of Pathology, Saint-Louis Hospital, Paris, France;
5Department of Internal Medicine, Saint-Louis Hospital, Paris, France;
6INSERM U553, Hoˆpital Saint-Louis, Paris, France and 7INSERM U429,
Hoˆpital Necker, Paris, France
Correspondence: Professor Ce´leste Lebbe´, Policlinique de Dermatologie,
Hoˆpital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris cedex 10,
France. E-mail: celeste.lebbe@sls.ap-hop-paris.fr
Abbreviations: CEC, circulating endothelial cell; CKS, classic Kaposi’s
sarcoma; EKS, endemic Kaposi’s sarcoma; KS, Kaposi’s sarcoma; KSHV,
Kaposi’s sarcoma-associated herpesvirus; PBMC, peripheral blood
mononuclear cell
In order to explore the pathogenic role of KSHV in CKS
and EKS, we aimed to see whether: (1) KSHV was detectable
in PBMCs from actual cases, and whether or not KSHV viral
load in PBMCs was similar in the two settings compared with
immunosuppressed patients; (2) circulating endothelial cells
(CECs) harboured the virus; (3) which clinical, histologic, and
immunologic features were associated with positive KSHV
viremia in such specific KS patients.
RESULTS
Eighty-one patients, whose characteristics are given in
Table 1, were included. The median age at enrollment was
67 years, whereas the median time from first symptoms of KS
was 6.7 years. Most patients had CKS whereas 11/81 (14%)
had EKS. Forty-nine patients (60%) had limited disease with
fewer than 10 lesions. Lymphedema was present in 32 (40%)
whereas painful disabling lesions were recorded in 17 (21%).
KS was progressive in 32 (40%) but only 25 (31%) required
systemic treatment (interferon n¼20, bleomycin n¼2, vin-
blastin n¼2, thalidomide n¼ 1) within 6 months after enrollment.
KSHV viremia occurred in 47 (58%) patients (median
value of KSHV viremia restricted to the 47 patients was
3.48 log (2.01–4.76)).
PBMCs sorting was performed for eight patients with
positive KSHV viral load in total PBMCs. As shown in
Table 2, three of eight (37.5%) had KSHV-infected B cells,
two of seven (28.5%) had infected monocytes, and only one
of eight (12.5%) had infected T cells. None had CEC-depleted
CD34þ cells infected by KSHV and 50% (4/8) of the patients
tested had CECs infected by KSHV. All had progressive or
stable KS (five progressive disease and three stable disease).
Although KSHV was detectable in total PBMCs in the eight
patients, KSHV remained undetectable in either subpopu-
lations in two patients. This result is probably related to the
cell loss during washes and to the low total viral load
(respectively 2.48 and 2.95 log). We tried to quantify the
number of separated CECs using the Malassez count; the
quantification of rosetted CECs was performed in triplicate,
and CECs were identified when bearing more than 10 beads
and a cell size in the range of 30–50 mm as described by
George et al. (1992, 1993). We found less than 1 CEC/ml of
peripheral blood among PBMCs of normal subjects (n¼ 5)
but 100 to 10,000 CEC/ml in the KS patients tested (n¼8).
Among immunologic parameters studied in our KS cohort,
we observed a significant increase of IL-2 and IFN-g
production by CD4 T cells as well as an increase of IFN-g
production by CD8 T cells compared to control patients
matched for age (Table 3). Increase of IL-2 production by
CD8 T cells was not significant. Moreover, the number of
lymphocytes, percentage of total CD3, CD3-HLA-DR, CD3-
CD25, and CD3-CD38 lymphocytes as well as percent of
total CD4, CD4-CD28, CD4-CD45RA, and CD4-CD45RO
lymphocytes were not significantly different between KS
patients and controls. No significant difference was also
Table 1. Main characteristics of patients
Mean value (SD)/or
number (%)
Sex ratio 4.4 (66 H, 15 F)
Age at inclusion 67 (14)
Time from first symptoms of KS (years) 6.7 (7.7)
Type of KS
Endemic KS 11 (14)
Classic KS 70 (86)
Previous systemic therapy 15 (19)
Current systemic therapy 6 (7)
Associated malignancy 7 (9)
Diabetes 11 (14)
Decision of systemic therapy within 6 months 25 (31)
Histologic form
Lymphangiomatosis 14 (20)
Patch 12 (17)
Plaque 11 (16)
Nodular 32 (46)
Number of lesions (n)
no0 5 (6)
n=1 13 (16)
1onp10 31 (38)
10onp50 26 (32)
50onp100 4 (5)
n4100 2 (2)
Painful lesions 17 (21)
Lymphedema 32 (40)
KSHV-positive viremia 47 (58)
F; female; H, M=male; KS, Kaposi’s sarcoma; KSHV, Kaposi’s sarcoma-
associated herpesvirus; SD, standard deviation.
Table 2. KSHV viral load in peripheral blood
mononuclear cells after magnetic cell sorting
(patients with positive KSHV viremia)
KSHV viral load (copies/microgramm of DNA)
Patient
CD19+
cells
CD2+
cells
CD14+
cells
CD146+
cells
CD146
CD34+ cells
KS
staging
1 o10 o10 o10 458 o10 PD
2 45 11 75 244 o10 PD
3 688 o10 o10 276 o10 SD
4 o10 o10 2,260 o10 o10 SD
5 o10 o10 o10 280 o10 PD
6 o10 o10 o10 o10 o10 PD
7 o10 o10 o10 o10 o10 SD
8 397 o10 ND o10 ND PD
KS, Kaposi’s sarcoma; KSHV, Kaposi’s sarcoma-associated herpesvirus;
ND, not done; PD, progressive disease; SD, stable disease.
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observed in percent of CD8 lymphocytes, of CD19 lympho-
cytes, and in percent of NKT and NK cells.
Using univariate analysis, detection of KSHV by PCR in
peripheral blood was significantly associated with EKS
versus CKS (P¼ 0.02), KS progression (P¼0.001), decision
of systemic therapy (P¼ 0.03), KS staging (P¼0.03),
lymphedema (P¼0.01), whereas it did not depend on the
histologic type, length of KS evolution, the presence of
painful KS lesions (Table 4). None of the immunologic
parameters studied was significantly associated with KSHV
viremia.
When all significant parameters were considered jointly
by multivariate analysis, only KS progression (P¼0.001) and
KS staging (as evaluate by the number of lesions) (P¼0.03)
remained significantly and independently associated with
positive KSHV viremia (Table 4).
DISCUSSION
The demographic, clinical, and histologic features of the 81
CKS and EKS patients reported in this study is in accordance
with previous reports. Like Friedman-Birnbaum et al. (1990),
we found a high prevalence of diabetes (15% in our series, all
type II with a median age of onset of 61 years; 16% in theirs),
whereas the rate of accompanying malignancies seems lower
than previously reported (9% – four prostate adenocarci-
noma, two T-cell lymphomas, and one polycythemia vera,
compared to 19% for Brenner et al., 2002). Up to 31% of
patients had an extension or progression of KS requiring
systemic therapy compared to 19% in the series of Brenner
et al. (2002). This difference may be related to differences in
patient population.
The detection rate of KSHV virus in PBMCs (58%) is
similar to our previously published observations (Lebbe et al.,
1997; Cattani et al., 1998; Boneschi et al., 2001). KSHV viral
load in PBMCs appears lower in CKS or EKS (3.48 log) versus
HIV or transplanted KS where median values were, respec-
tively, 4.13 and 4.60 log in previously published data (Pellet
et al., 2001, 2002). This could be related to an increased viral
reactivation due to immunosuppression or a higher tumor
burden in epidemic or post-transplant KS. The latter hypo-
thesis is supported by the fact that KSHV viremia was signifi-
cantly associated with disease progression and tumor burden,
Table 3. Significant differences in intracellular
cytokines expressed as percent of T CD4 or T CD8
positive lymphocytes
Kaposi Controls
Intracellular cytokines N Mean (SD) Mean (SD) P-value
CD4 IFN-g 29 32.7 (18.3) 15.3 (9.8) 0.012
CD4 IL-2 29 60.2 (15.1) 21.6 (12.2) o0.001
CD8 IFN-g 29 68.8 (21.6) 44 (16.3) 0.018
Median values and standard deviation for the KS patients and 10 controls
matched for age.
KS, Kaposi’s sarcoma; KSHV, Kaposi’s sarcoma-associated herpesvirus;
N, number; SD, standard deviation.
Table 4. Parameters associated with positive KSHV viremia
Crude OR (95% CI) P-value Adjusted OR (95% CI) P-value
KS progression 9.8 (3.4–28.0) o0.001 14.2 (2.7–73.9) 0.0017
Time from first symptoms of KS 1.5 (0.6–3.7) 0.05
Endemic KS versus classic KS 8.9 (1.08–73.5) 0.02 6.3 (0.6–71.1) 0.14
Age at enrolment (less than 60 vs superior or equal to 60 years) 0.9 (0.3–2.3) 0.8
Age at first symptoms of KS (less than 60 vs superior or equal to
60 years)
0.4 (0.2–1.1) 0.07 0.7 (0.2–2.3) 0.56
Decision of systemic therapy 3.3 (1.5–9.2) 0.03 0.4 (0.06–2.3) 0.28
Previous systemic therapy 0.8 (0.3–2.5) 0.7
Current systemic therapy 0.7 (0.1–3.7) 0.7
Histologic form (S vs A, I, CM) 0.9 (0.3–2.3) 0.8
Number of lesions (more than 1 vs equal or less than 1) 4.4 (1.6–12.0) 0.03 6.6 (1.3–35.1) 0.03
Painful lesions 3.0 (0.9–10.1) 0.07 1.4 (0.3–7.6) 0.7
Lymphedema 3.5 (1.3–9.5) 0.01 1.3 (0.3–6.4) 0.7
Intracellular cytokines
CD4 IFN-g 1.0 (0.99–1.01) 0.3
CD8 IFN-g 1.0 (0.99–1.01) 0.5
CD4 IL-2 1.0 (0.99–1.01) 0.3
CD8 IL-2 1.0 (0.99–1.01) 0.7
95% CI, 95% confidence interval; A, angiomatous; CM, cellular mixt; I, inflammatory; KS, Kaposi’s sarcoma; KSHV, Kaposi’s sarcoma-associated
herpesvirus; OR, odds ratio; S, sarcomatous.
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whereas no immunologic parameter was apparently involved.
Although the association between KSHV viremia and KS
progression has already been demonstrated in HIV-infected
patients by us (Pellet et al., 2001) and by others (Marcelin
et al., 2004), it has never been demonstrated in non-HIV-
infected KS patients. The low number of patients (11) included
in Marcelin et al.’s study (2004) probably explain why these
authors failed to demonstrate a relationship between HIV-
negative KS extension and viral load in PBMCs.
As already demonstrated by others using a similar
methodology (Ambroziak et al., 1995; Harrington et al.,
1996; Henry et al., 1999), our results show that KSHV can
infect B lymphocytes and monocytes. In only one patient
KSHV sequences were found in the T lymphocytes at a very
low viral load (just above the limit of the test sensitivity). It is
therefore very difficult to assume that T cells are infected with
KSHV from these results. Anti-S-endo-1 is a pan-endothelial
monoclonal antibody, and S-endo-1 (CD146) is ubiquitously
and highly expressed in the majority of human endothelial
cells of different types of vessels, including lymphatic
vasculature (George et al., 1991; Bardin et al., 1996). The
anti-S-endo-1 antibody recognizes mature endothelial cells
and endothelial cell progenitors obtained in culture (Ingram
et al., 2004). Therefore, it could recognize mature endothelial
cells and young cells from circulating progenitors in the
blood. Our results suggest that CD34þ cells infected by
KSHV are CECs. Solovey et al. (1997) found a mean of
2.6 CEC/ml of peripheral blood in normal subjects, but a
mean of 22.8 CEC/ml in patients with acute painful crisis of
sickle cell anemia. George et al. (1991, 1992, 1993), whose
methodology we used, found less than 1 CEC/ml in normal
subjects but a mean of 162 CEC/ml (ranging from 0 to 1600)
in Mediterranean spotted fever subjects before treatment. Our
CEC counts accord with those in the literature with regard to
healthy subjects but the number of CECs in Kaposi subjects
seems elevated compared to CECs count in other clinical
situations. As the CD146þ population is a minority among
PBMCs and because of cell loss during washings, we believe
that we have probably underestimated the CD146þ
population. Although we did not succeed in visualizing
KSHV-infected CECs by FACS analysis and could not
exclude contaminating cells in the CD146þ population,
the 100- to 100,000-fold difference between the numbers of
CD146þ cells separated from normal and KS individuals
could be related to KS pathogenesis. Indeed, KS spindle cells
are thought to be derived from either KSHV-infected
endothelial precursors, or from mature lymphatic and
blood endothelial cells, with KSHV having induced lymph-
atic gene expression (Hong et al., 2004; Wang et al., 2004).
Therefore, two non-exclusive hypotheses can be drawn
from the presence of KSHV in the CECs: circulating
CD146 cells could be mature spindle cells that separate
from the KS lesions and migrate toward the peripheral blood,
or KSHV-infected CECs could be spindle cell precursors
migrating from the peripheral blood toward tissues to
colonize target tissues and then develop into KS lesions.
The latter hypothesis could be paralleled with Barozzi et al.
(2003) who detected the presence of the donor neoplastic
KSHV-CD34-infected cells in the KS lesions from five of eight
kidney recipients.
Regarding immunologic analysis, our results show that KS
patients do not have lymphocyte counts significantly lower
than age-matched controls, which contrasts with the findings
of Touloumi et al. (1999). Similarly, KS patients did not
significantly differ from controls in respect of total T-cell
count, CD4 and CD8 T-cell subpopulation, or in B cells,
whenever percentages or total values are considered. This
agrees with published findings, except for those of Touloumi
et al. (1999) where CD4 T lymphocytes were fewer in KS than
in sex-and age-matched controls. Notably we found an
increase in IFN-g-expressing T cell, in the CD8, but also and
to a higher extent in the CD4-positive population as well as
an increase in IL-2 CD4 T cells among KS patients. Our
findings can be compared to those of Sirianni et al. (1998),
although our methodology using intracellular cytokine flow
cytometry may reflect a more relevant physiological impact
and allows discrimination between CD4 and CD8 T cells.
Sirianni et al. (1998) assessed cytokine production of PBMCs
isolated from KS patients after 72 hours of in vitro stimulation
by phyto-hemagglutinin. They showed a preferential IFN-g
expression both in CKS and AIDS KS. Moreover, they showed
high level of IFN-g production by KS infiltrating CD8 T cells.
Whereas positive KSHV viremia was not associated with IFN-
g-producing T cells in KS patients, nor with any other
immunologic marker, Fiorelli et al. (1998) have demonstrated
a relationship between IFN-g and HLADRþ T cells infiltrat-
ing tissues and the presence of KSHV in the same specimen.
Physiological immune responses to herpesvirus involve both
T CD8þ and T CD4þ cells (Amyes et al., 2003; Gamadia
et al., 2003). Although IL-2 and IFN-g intracellular staining
was performed after non-specific stimulation, we can
suppose that detected cells include KSHV-specific cells that
may contribute to the control of KSHV infection. Recently,
cytomegalovirus-specific IFN-g-producing CD4 effector cells
have been described indispensable in protection against
cytomegalovirus disease (van Leeuwen et al., 2004). How-
ever, from our data, the detection of IFN-g-producing CD8 or
CD4 cells was not associated with negative KSHV viremia.
Moreover, IL-2/IFN-g T CD4þ cells have been described to
be associated with antigen persistence and low antigen levels
in chronic HSV, EBV, and cytomegalovirus infections (Harari
et al., 2005). Those secreting IL-2 and IFN-g T CD4þ cells
found to be significantly associated with KS could be a
marker of KSHV chronic infection.
As neither Sirianni et al. (1998) nor us measured KSHV-
specific IFN-g production, we cannot exclude involvement of
T cytokine production driven by other unknown stimuli. IL-2
and IFN-g are Th1 cytokines with an established role in
defense against viral and other pathogens and in the
induction of immune-mediated inflammatory response. The
strong association between Th1 profile and KS disease could
suggest that Th1 pattern may contribute to the development
of KS disease.
In nude mice, IFN-g has been shown to induce endothelial
cells to acquire phenotypical and functional characteristics of
KS spindle cells and to induce angiogenic lesions (Fiorelli
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et al., 1998). IFN-g is able to induce KSHV reactivation in
vitro (Chang et al., 2000). Worsening of KS has been reported
after treatment with IFN-g. Therefore, our data do not provide
any evidence of immunosuppression in CKS or EKS. We did
not assess KSHV-specific responses and therefore cannot
exclude a KSHV-specific immune defect that would allow the
virus to escape immune cell control. We show physiological
T-cell response to a herpesvirus infection. A pathogenic role
of IFN-g in KSHV reactivation and KS progression can
therefore be suggested.
In conclusion, we have provided evidence that, whatever
the clinical context of KS, KSHV viremia is associated with
tumor burden and KS progression. In CKS and EKS popula-
tions, KSHV viral load is less than that in immunosuppressed
patients. We have shown that KSHV can be detected within
CECs, and that KSHV viremia could be an indicator of
circulating mature or precursor spindle cells. The variation in
KSHV viral load is clearly insufficient to permit the
monitoring patients with KSHV viremia. When no specific
immunosuppression is evident, the numerous circulating
activated IFN-g-producing T cells suggest that both classic
and EKS patients have a close to normal immunologic
parameters to viral infection.
MATERIALS AND METHODS
KSHV viremia and various immunologic parameters were measured
in 81 patients suffering from non-HIV-related KS followed in our
institution from January 1994 to January 2002. Those with
histologically confirmed KS and with at least a 6 months follow-up
were included in this cross-sectional study.
The study was approved by the medical ethical committee of
Saint-Louis Hospital. The study was conducted according to the
Declaration of Helsinki Principles. Patients gave their written
informed consent.
Main clinical measures at enrollment
The following parameters were recorded: age at enrollment and at
KS diagnosis, histologic type, that is, patch, plaque, nodular, and
lymphangiomatosis (Chor and Santa Cruz, 1992), and KS extension
classified from 0 to 5 as follows: no lesion, 1 lesion, 1–10 lesions,
10–50 lesions, 50–100 lesions, and 4100 lesions. The interval time
from KS diagnosis was also recorded along with the presence of
lymphedema, painful lesions, past or current history of specific
treatment for KS. The disease progression was defined as proposed
by Krown et al. (1989). Patients were classified as having endemic
KS when they came from sub-Saharan Africa, or as having CKS when
they came from Mediterranean countries.
Control subjects
For immunologic parameters study, control patients undergoing
surgery, without KS, KSHV sero-negative, and matched for age were
selected.
DNA extraction and KSHV quantitative viral load
PBMCs were obtained from blood samples after separation with
Ficoll. DNA was extracted using QIAamp blood DNA extraction kit
(Qiagen, Hilden, Germany) and was amplified using real-time
quantitative PCR performed on Light Cycler 1.3 (Roche, Neuilly Sur
Seine, France) in the presence of an internal probe within orf 26 as
described by Kennedy et al. (1997). PCR conditions and primers
sequences have been previously described (Pellet et al., 2001).
Dilutions of known amounts (10–107 copies) were used for the
standard curve. This method allowed us to quantify from 10 to 107
copies of this fragment.
Flow cytometry analysis
Lymphocyte immunophenotyping was performed on fresh whole
blood samples by direct 4- 3- or 2-color immunofluorescence.
CD3, CD4 and CD8 T cells, activated CD25, HLA-DR and CD38
T cells, competent CD28 CD4 and CD8 T cells, memory CD4RO
and CD45RA CD4 T cells as well as NK CD3-CD16þCD56þ and
B CD19 cells were quantified using standardized procedures
(Fournier et al., 2001). The following monoclonal antibodies from
Becton Dickinson (San Jose, CA) were used: CD45-FITC or -PerCP,
CD14-PE, CD3-FITC or -PerCP, CD4-FITC, -PE or -APC, CD8-PE,
CD2-FITC, CD16þCD56-PE, CD19-PE, CD28-PE, CD25-PE, HLA-
DR-PE, CD38-PE, CD45RA-FITC, CD45RO-PE. Appropriate isotype-
matched controls were carried out on each sample. Five thousand
gated lymphocytes were analyzed with a FACScalibur analyzer
(Becton Dickinson). Lymphocyte gate purity was X98%.
Intracellular cytokines
Intracellular IFN-g and IL-2 were detected by flow cytometry on
activated lysed whole blood with a scatter gate on the CD3þ T
population (Sewell et al., 1997).
Fresh whole blood sodium heparinate samples were activated in
the presence of phorbol 12-myristate 13 acetate (25 ng/ml, Sigma, St
Louis, MO), and calcium ionophore (ionomycin 1mg/ml, Sigma) for
4 hours at 371C –5% CO2 in the presence of brefeldine A (BFA 10 ml/
ml, Sigma). Double-color surface staining was then performed with
FITC- or PE-conjugated anti-CD4 or anti-CD8 and PerPC-anti-CD3
monoclonal antibodies (Becton Dickinson). Cells were then per-
meabilized with permeabilizing solution (Becton Dickinson) and
stained with FITC-anti-IFN-g or phycoerythrin-anti-IL-2 (Becton
Dickinson). Isotypic controls, permeabilizing control (Bcl-2-FITC,
25 m/ml, Dako, Glostrup, Denmark), and activation control (CD69-
PE, Becton Dickinson) were performed at the same time. 5,000 lym-
phocytes were initially gated by FSC/SSC and secondary set on CD3.
Results were expressed as % of the CD4 and CD8 T-cell
populations.
Cell separations
PBMC samples of eight patients suffering from CKS with positive
KSHV viremia were available for cell separation. Forty million
PBMCs were obtained from lithium heparinate-treated blood speci-
mens after Ficoll separation.
The majority (B and T lymphocytes, monocytes) and minority
(CD146 and CD34 cells) PBMC subpopulations were isolated using
immunomagnetic Dynabeads (Dynal, Osb, Norway). Immunomag-
netic separations were conducted following the manufacturer’s
protocol. CECs were depleted first using immunomagnetic Dyna-
beads coated in our laboratory with mouse anti-human CD146
(S-endo-1) MoAb (Biocytex, Marseille, France) as a second layer, as
described by George et al. (1992). CD146-CD34þ cells, mono-
cytes, B lymphocytes, and then T lymphocytes were then separated
using standardized coated Dynabeads CD34, CD14, CD19, and
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CD2, respectively. Dynabeads depletion was assessed to be
complete in these experiments. Specificity of the anti-S-endo-1
antibody was tested using human microvascular endothelial cells
and human umbilical vein endothelial cells as positive controls and
BC-3 cells (KSHV-infected pleural effusion lymphoma cell line) as
negative control. After selection with anti-S-endo-1 coated Dyna-
beads of sequential dilution of human umbilical vein endothelial
cells cells in PBMCs from a healthy patient, about 80% of the cells
remained, which means that 20% were lost during washes. Using
microscopy, rosetted human umbilical vein endothelial cells
appeared large, with at least 10 beads on their surface. We could
observe less than 1% of contaminating cells that were small and with
fewer than three beads on the surface.
Statistical analysis
Patients with positive KSHV viremia (n¼ 47) and those without
(n¼ 34) were compared for several clinical and histologic variables,
using the w2. All significant variables at 0.2 level were included in a
multiple logistic regression model. The results are presented with
odds ratios and 95% confidence intervals.
Flow cytometry data and expression of intracellular cytokines
were compared by analysis of variance. P-values were corrected for
multiple tests with the Hochberg–Benjamini method (Hochberg and
Benjamini, 1990). All the statistical analyses were performed using
SAS 8.2 software.
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